These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22449364)

  • 1. Hematological malignancies: a primer.
    Haddad RY
    Dis Mon; 2012 Apr; 58(4):151-2. PubMed ID: 22449364
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modern therapy of hematologic malignancies].
    Trnĕný M
    Cas Lek Cesk; 2001 Nov; 140(23):711-6. PubMed ID: 11787232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.
    Cremer B; Sandmaier BM; Bethge W; Lange T; Goede V; Holtick U; Hallek M; Hübel K
    Onkologie; 2011; 34(12):710-5. PubMed ID: 22156452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted and tailored therapy in hemato-oncology: vision for the 21st century.
    Shpilberg O; Ben-Bassat I; Raanani P
    Isr Med Assoc J; 2006 Dec; 8(12):843-4. PubMed ID: 17214100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NKT cell-mediated immunotherapy for hematological malignancies].
    Fujii S
    Rinsho Ketsueki; 2007 Mar; 48(3):188-99. PubMed ID: 17441475
    [No Abstract]   [Full Text] [Related]  

  • 6. Towards immunogene therapy of hematological malignancies.
    Ivanov R; Hagenbeek A; Ebeling S
    Exp Hematol; 2006 Mar; 34(3):251-63. PubMed ID: 16543059
    [No Abstract]   [Full Text] [Related]  

  • 7. New frontiers of therapy in hemato-oncology.
    Prabhash K; Bapsy PP
    J Assoc Physicians India; 2003 Nov; 51():1123-4; author reply 1124. PubMed ID: 15260408
    [No Abstract]   [Full Text] [Related]  

  • 8. Newer monoclonal antibodies for hematological malignancies.
    Castillo J; Winer E; Quesenberry P
    Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advances in medical oncology].
    Shi YK
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):305-10. PubMed ID: 16900620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A 2021 inventory in oncology news].
    Bay JO; Bouleuc C; Firmin N; Gandemer V; Magne N; Orbach D; Penel N; Rodrigues M; Thiery-Vuillemin A; Wislez M; L'Allemain G; Sabatier R; Robert J;
    Bull Cancer; 2022 Jan; 109(1):8-19. PubMed ID: 34980367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rituximab and hematological malignancy].
    Hatake K; Mishima Y; Terui Y
    Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Major therapeutic advances and new perspectives in onco-hematology].
    Bay JO; Guièze R; Ravinet A; Lemal R; Xhaard A; Bailly S; Moluçon-Chabrot C; Hermet E; Biau J; Verrelle P; Peffault de Latour R; Tournilhac O
    Bull Cancer; 2013 Jun; 100(6):587-99. PubMed ID: 23735575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies.
    Robertson MJ; Pelloso D; Abonour R; Hromas RA; Nelson RP; Wood L; Cornetta K
    Clin Cancer Res; 2002 Nov; 8(11):3383-93. PubMed ID: 12429625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation.
    Puig N; Caballero MD; Alcoceba M; Sebastián E; Balanzategui A; Sarasquete ME; García-Sanz R; González-Díaz M
    Ann Hematol; 2011 Feb; 90(2):227-9. PubMed ID: 20506021
    [No Abstract]   [Full Text] [Related]  

  • 16. Expanding role of monoclonal antibodies in the treatment of hematologic malignancies. Highlights from the 41st annual meeting of the American Society of Hematology. New Orleans, Louisiana, USA. December 3-7, 1999. Abstracts.
    Oncology (Williston Park); 2000 Mar; 14(3 Suppl 1):5-60. PubMed ID: 10808400
    [No Abstract]   [Full Text] [Related]  

  • 17. Managed care considerations: hematologic cancer as a chronic disease.
    DePue RJ
    Manag Care; 2008 Jul; 17(7 Suppl 6):preceding table of contents. PubMed ID: 19119536
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of interleukin-2--based immunotherapy in hematological malignancies].
    Ackerstein A; Toren A; Slavin S; Nagler A
    Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
    [No Abstract]   [Full Text] [Related]  

  • 20. [Late infectious complications after high-dose therapy and autologous blood stem cell transplantation].
    Metzner B; Grüneisl R; Gebauer W; Reschke D; Ost E; Müller TH; Reichert D; Rosien B; Del Valle F; Zirpel I; Kohse KP; Schunter F; Illiger HJ
    Med Klin (Munich); 2002 Nov; 97(11):650-8. PubMed ID: 12434273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.